[full_width_section bg_pos=”Left Top” bg_repeat=”No-Repeat” text_color=”Dark” image_url=”” top_padding=”60″ bottom_padding=”20″ background_color=”#f5f5f5″]
The Velius Team
Our team has vast and varied industry experience. Successful in his or her own field, each member’s pursuit of and reputation for excellence results in a whole that is greater than its parts.[/full_width_section] [full_width_section bg_pos=”Left Top” bg_repeat=”No-Repeat” text_color=”Dark” image_url=”” top_padding=”30″ bottom_padding=”30″ background_color=”##f5f5f5″]
[one_fourth] Joel R. Studin, MD, FACS [/one_fourth] [one_fourth] CEO [/one_fourth] [one_half_last]Dr. Studin is a plastic and reconstructive surgeon credited with medical device and pharmaceutical patents, both domestically and around the world. Prior to Velius, Dr. Studin founded, built and and sold two technology related regional and global companies.[/one_half_last]
[one_fourth] Daniel Easton [/one_fourth] [one_fourth] EVP – Marketing [/one_fourth] [one_half_last]
Prior to Velius, Mr. Easton was a senior marketing executive responsible for creating major campaigns for such brands as Pepsi, Lipitor and Reach Toothbrush.
[one_fourth] Jim Dunn [/one_fourth] [one_fourth] EVP – Sales [/one_fourth] [one_half_last]
Prior to Velius, Mr. Dunn was a senior sales executive for Unilever, Max Factor and Flents Pharmaceuticals.
[one_fourth] Steve Levinson [/one_fourth] [one_fourth] VP – Operations and Purchasing [/one_fourth] [one_half_last]
Prior to Velius, Mr. Levinson was a purchasing agent for Nestle, and subsequently VP of purchasing and operations for ET Brown Drug Company and then Adrienne Arpel.
[one_fourth] Bob Giuliano, RPh [/one_fourth] [one_fourth] EVP – Research and Development [/one_fourth] [one_half_last] Mr. Giuliano served as director of pharmacy for two New York City hospitals. He has extensive experience in drug formulation and custom drug compounding. [/one_half_last]
[one_fourth] Dudley Harris [/one_fourth] [one_fourth] Regulatory and Quality Control [/one_fourth] [one_half_last] Mr. Harris served as Director of Compliance for an FDA field office before becoming a Regional Director for the FDA. He is an expert in pharmaceutical cGMP and functions as a consultant. [/one_half_last]
[one_fourth] Laura Sabbagh, CPA [/one_fourth] [one_fourth] Controller [/one_fourth] [one_half_last] Ms. Sabbagh has over 20 years experience conducting and overseeing audits of public and private companies in senior positions at Margolin, Winer u0026amp; Evens, LLP, Nussbaum Yates u0026amp; Wolpow, LLP, and Mahoney Cohen. [/one_half_last]
[one_fourth] Jerry Katz [/one_fourth] [one_fourth] CFO [/one_fourth] [one_half_last]Jerry Katz is a Certified Public Accountant. He has been practicing Public Accounting since 1977 with an expertise in health care. He has owned and operated numerous long-term care facilities. As such, he has a complete understanding of the issues and challenges of operating a business – including formation, the start-up phase, staffing, cost containment, insurance requirements, marketing, licensure and ultimately the negotiation and sale of a business. Mr. Katz received his Bachelor of Arts (B.A.’76) degree in Economics from UCLA and an MBA from Loyola Marymount University (MBA ‘80). Mr. Katz is involved a number of philanthropic endeavors including the position of National Treasurer of an International Foundation. Along with his wife, in 2014 they formed the Jerry N. u0026amp; Linda J. Katz Foundation to assist other 501(c)(3) non-profits primarily in the health and educational arenas. Mr. Katz served for six years on the Loyola Marymount University Board of Regents as continues to belong to the Advisory Council to the College of Business Administration at Loyola Marymount University.
[full_width_section bg_pos=”Left Top” bg_repeat=”No-Repeat” text_color=”Dark” image_url=”” top_padding=”” bottom_padding=”” background_color=””]
[divider line_type=”Full Width Line”]
Board of Directors
[one_fourth] Joel R. Studin, MD, FACS [/one_fourth] [three_fourths_last] Dr. Studin is a plastic and reconstructive surgeon and past hospital Chief of Plastic Surgery. He is credited with several pharmaceutical and medical device patents. Prior to Velius, Dr. Studin founded, built and and sold two technology related regional and global companies. His business background combined with his clinical experience provide valuable insight in guiding Velius. Dr. Studin received his Bachelor’s Degree from The University of Rochester, his M.D. Degree from The Mount Sinai School of Medicine in New York, his Fellowship training in Reconstructive Microsurgery at St. John’s Medical Center and his Laser Surgery training at Harvard Medical School. He is Board Certified by the American Board of Plastic Surgery. [/three_fourths_last]
[one_fourth] Lester Rosenkrantz [/one_fourth] [three_fourths_last] Mr. Rosenkrantz is a Wall Street veteran with decades of experience in all facets of the micro and mid-cap equity markets. During his career he has been instrumental in financing many companies both privately and publicly. Prior to joining Cameron, an investor relations firm, in 2001, he spent 38 years in the investment banking and brokerage business, including a 17 year tenure as CEO of Rosenkrantz Lyon u0026amp; Ross, Inc., a NYSE-member firm. As an investment banker, Lester garnered in-depth experience representing companies and their management as they interacted with their boards of directors as well as investment bankers, analysts, investors, attorneys and accountants. Lester graduated from Pennsylvania State University with a B.S. in Business Administration. [/three_fourths_last]
[one_fourth] William A. Landman [/one_fourth] [three_fourths_last] Since 1987, Bill Landman has served as a Senior Managing Director for CMS Companies. He is one of the managing partners for this 40-year-old boutique investment firm, overseeing $2 billion of investments in the areas of private equity and real estate. From 1977 to 1987, Mr. Landman was a partner in Reich u0026amp; Landman, with expertise in transactional corporate practices and the representation of professional athletes. Mr. Landman currently serves as a Member and Board Chairman of Thomas Jefferson University Hospital and Chairman of the Audit Committee and Board Member of Jefferson Health System. He is a board member of Cetero, Inc., Biltmore Capital Group, Liberty Restaurant Group and Caivis Acquisition Corp. Mr. Landman previously served as a Director and Chairman of the Compensation Committee and member of Audit Committee of Russ Berrie u0026amp; Company, Inc. (NYSE) and as a Managing Director of KRG Capital Partners, a $705M private equity firm in Denver. He also was the President of the Philadelphia Israel Chamber of Commerce; Vice President u0026amp; Treasurer, Philadelphia Jewish Community Center; and Member of Federation of Young Leadership Cabinet. Mr. Landman is the author of “The Alternative Edge? Boosting Returns and Reducing Risk with Private Fund Investing”, a user friendly guide to maximize returns on alternative investments. Mr. Landman holds a B.A. from the University of Pittsburgh and a J.D. from the University of Pittsburgh School of Law. [/three_fourths_last]
[one_fourth] Tom Jennings [/one_fourth]
[three_fourths_last] Mr. Jennings has a 25 year career as an independent Labor consultant to nationwide fortune 500 companies such as Anheuser Busch N.A., Albertsons Inc., Supervalue Inc., Praxair, Stop and Shop Companies and Hu0026amp;M Container. Tom served as the Chairman of STS Inc. which was a supplier of specialized labor forces throughout 48 states. He was also the Founder and Chairman of the Board of The Westchester Hawks, a non-profit youth organization based in New York; Principal of TJJ Capital Funding; Founder and Board member of Greater Northern New Jersey Development Corp. and Managing Member Of STS Southern, LLC, which was heavily involved in the Hurricane Katrina Relief Effort. [/three_fourths_last]
[one_fourth] Andy Oxenhorn [/one_fourth]
After an early successful career marketing home electronics, Mr. Oxenhorn went on to become President of MB Quart International, a global electronics company headquartered in Germany. In 1996, he was recruited to become president and a partner at JL Audio, Inc, a privately held company headquartered in Miramar, Florida. JL Audio is a leading brand for premium car, home and marine audio equipment worldwide. Under Mr. Oxenhorn’s guidance, JL Audio expanded its product offerings and quadrupled sales to over $63 million annually. JL Audio is the only brand in the audio industry that has remained committed to manufacturing the majority of its products in their US factory. Mr. Oxenhorn is a hands-on manager whose duties for the company include Marketing and Sales, along with Logistics and Finance. Due in large part to Mr. Oxenhorn’s guidance, JL Audio’s products are now sold in 74 different countries throughout the world. Mr. Oxenhorn is a graduate of the University of Vermont and did his postgraduate studies in the MBA program at Babson College.
[one_fourth] Jerry Katz [/one_fourth]
Jerry Katz is a Certified Public Accountant. He has been practicing Public Accounting since 1977 with an expertise in health care. In 1983, Mr. Katz, formed Katz Accountancy Corporation. The services the firm provides included financial statement preparation, tax planning and preparation, and management consulting. In addition to an intimate knowledge of accounting and taxation, Mr. Katz, understands the operational issues surrounding the running and managing of a small to medium sized business. For eight years, Mr. Katz ran a 71 unit assisted living facility which a Company that he and his wife formed, built, financed, licensed and operated. He ran it until the Company was sold for a near record amount in 2015. Additionally, along with his wife, since 1993 they have owned and operated numerous long-term care facilities. As such, he has a complete understanding of the issues and challenges of operating a business – including formation, the start-up phase, staffing, cost containment, insurance requirements, marketing, licensure and ultimately the negotiation and sale of a business. Mr. Katz received his Bachelor of Arts (B.A.’76) degree in Economics from UCLA and an MBA from Loyola Marymount University (MBA ‘80). Mr. Katz is involved a number of philanthropic endeavors including the position of National Treasurer of an International Foundation. Along with his wife, in 2014 they formed the Jerry N. u0026amp; Linda J. Katz Foundation to assist other 501(c)(3) non-profits primarily in the health and educational arenas. Mr. Katz served for six years on the Loyola Marymount University Board of Regents as continues to belong to the Advisory Council to the College of Business Administration at Loyola Marymount University. Mr. Katz is a member of Beta Gamma Sigma, an honorary business fraternity. Through his career, Mr. Katz has been a guest lecturer for several health care associations.
FDA Advisory Team
[one_fourth] Jonathan Wilkin, MD, FAAD [/one_fourth] [three_fourths_last] Dr. Wilkin is the founding director of the Division of Dermatology and Dental Products at the US Food and Drug Administration. Dr. Wilkin remains active in regulatory matters, of American Academy of Dermatology’s Ad Hoc Task Force on Academy’s Efforts with the FDA. Prior to FDA, he served as Director, Dermatology Division and Professor of Medicine and Pharmacology Departments, of The Ohio State University. Prior to Ohio State University, he served as Chief of Dermatology section, Hunter Holmes McGuire Veterans Administration Medical Center in Richmond, Virginia. Dr. Wilkin served as the Chairman of medical advisory board for the National Rosacea Society from 1998 to 2012. Dr. Wilkin is a fellow of both the American College of Physicians and American Academy of Dermatology. He is a diplomate of both the American Board of Clinical Pharmacology and the American Board of Dermatology. He has over 130 publications in dermatology and clinical pharmacology. [/three_fourths_last]
[one_fourth] Mark Kramer [/one_fourth] [three_fourths_last] Mr. Kramer established and led FDA’s Office of Combination Products from its inception in 2002 until 2007, when he left the Agency to become Regulatory Affairs Executive at GE Healthcare, a position he held through July 2010. Since that time he has consulted for many companies. Mark’s experience both as a regulator and as a regulatory affairs leader at a $17B global medical products company, gives him a comprehensive understanding of the complex laws, regulations, regulators, and review processes, as well as the practical experience that can only be gained in the “real world.” Mark currently serves on the Board of Directors of the Regulatory Affairs Professional Society (RAPS). [/three_fourths_last]
Scientific Advisory Team
[one_fourth] James G. Kreuger, M.D., PH.D. [/one_fourth] [three_fourths_last]Dr. Krueger received his bachelor’s degree from Princeton University in 1979, his Ph.D. from The Rockefeller University in 1984 and his M.D. from Cornell University Medical College in 1985. He came to Rockefeller as a guest investigator in the Laboratory for Investigative Dermatology, was appointed assistant professor in 1990, associate professor and head of lab in 1995 and professor in 2003. Dr. Krueger has held positions at The Rockefeller University Hospital since 1989. In 2006 he became codirector of the Center for Clinical and Translational Science, established by a Clinical and Translational Science Award from the National Center for Research Resources of the National Institutes of Health. Dr. Krueger was medical director and program director of the General Clinical Research Center from 1996 to 2006 and currently directs the Milstein Medical Research Program, which conducts new clinical studies of the pathogenesis of melanoma and other pigmentory diseases.
In 2010 Dr. Krueger won the Astellas Award in Public Health from the American Academy of Dermatology as well as the Farber Award from the Society of Investigative Dermatology. In 2006 Dr. Krueger received the E.H. Ahrens Jr. Award for clinical research from the Association for Patient-Oriented Research. He is also a recipient of two awards from the American Skin Association: the Distinguished Achievement Award and the Psoriasis Research Achievement Award, both granted in 2001. Dr. Krueger is a member of the American Society for Clinical Investigation and the Association of American Physicians.
Dr. Krueger uses histological and genomic approaches to study psoriasis as a model type 1 inflammatory disease. His work has implications for other common T cell mediated inflammatory diseases, including rheumatoid arthritis and inflammatory bowel disease, which have similar immunological phenotypes. Dr. Krueger focuses on the study of cutaneous inflammation and autoimmune mechanisms in human skin. His research is fundamentally rooted in “bench-to-bedside” science, combining the clinical study of new medical therapeutics with laboratory study of relevant immunopathogenic mechanisms in human cells and tissues. The Krueger laboratory conducts clinical research on patients with psoriasis vulgaris within The Rockefeller University Hospital. They treat patients with a wide variety of engineered immune agonists or antagonists in order to stimulate or inhibit molecular control points for the restoration of normal immune responses. By combining novel immune-directed therapeutics with large-scale study of gene expression (using gene chips and real-time RT-PCR reactions), an approach called pharmacogenetics, they seek to elucidate the molecular pathways that cause pathogenic inflammation and regulate normal human immune responses.More experimental immunotherapeutics have been assessed in clinical studies in psoriasis than any other human inflammatory disease. Dr. Krueger’s group has pioneered a number of successful treatments, including some that act on T cells, one that antagonizes specific inflammatory cytokines and one that utilizes a type of ultraviolet light with immunomodulatory properties.The lab-based research accompanying Dr. Krueger’s clinical trials includes the study of T cell, dendritic cell and keratinocyte activation responses using techniques including cell culture, flow cytometry and biochemical analysis. His group is also studying expression of a defined set of proinflammatory genes through real-time PCR and many other genes through genome-wide statement studies using DNA arrays. They defined the first disease classification set for psoriasis using chip-based approaches and recently determined a specific genetic and immunological signature that differentiates psoriasis from the closely related skin disorder called atopic eczema.Dr. Krueger’s research in healthy skin showed that a previously unknown population of dendritic cells exists alongside macrophages in the skin. Other recent work by members of the Krueger lab showed that a newly discovered immune cell, Th17, plays a central role in psoriasis and could serve as a target for future therapies. And by investigating the contribution of activated T lymphocytes, Dr. Krueger has found that psoriasis may be induced by tissue-infiltrating T lymphocytes, which trigger keratinocytes into a physiologically regulated wound repair pathway of hyperplasia and altered differentiation. [/three_fourths_last]
[one_fourth]Professor Roger Smith MA, VetMB, PhD, DEO, DipECVS, MRCVS [/one_fourth] [three_fourths_last] Dr. Smith is Professor of Equine Orthopaedics at the Royal Veterinary College at The University of London. He currently divides his time equally between running the orthopaedic service within the RVC and continuing to direct research into equine tendon disease. He qualified as a veterinary surgeon from Cambridge University in 1987 and, after 2 years in practice, returned to academia to undertake further clinical training as a Resident in Equine Studies at the Royal Veterinary College. Following his residency, he undertook a 3 year research project culminating in the award of a PhD for his studies on the extracellular matrix of equine tendon. He remained at the Royal Veterinary College, first as a Lecturer in Equine Surgery, then as Senior Lecturer in Equine Surgery before his appointment to a Professorship in December 2003. [/three_fourths_last]
[one_fourth]Richard D. Granstein, M.D. [/one_fourth] [three_fourths_last] Richard D. Granstein, M.D. is the George W. Hambrick, Jr. Professor and Chairman of the Department of Dermatology at the New York Weill Cornell Medical Center of New York-Presbyterian Hospital. Dr. Granstein obtained his undergraduate education at the Massachusetts Institute of Technology and his medical education at the UCLA School of Medicine. After completing his internship in 1979, he trained in dermatology at the Massachusetts General Hospital. As a Research Fellow, Dr. Granstein studied immunology and tumor biology at the National Cancer Institute-Frederick Cancer Research Facility and at Harvard Medical School. Dr. Granstein joined the faculty of the Department of Dermatology at Harvard Medical School and the Massachusetts General Hospital in 1984. In 1995 he left Harvard to become Chairman of the Department of Dermatology at the Weill Medical College of Cornell University and Dermatologist-in-Chief at the New York Weill Cornell Medical Center of New York-Presbyterian Hospital. Dr. Granstein’s research interests center on the regulation of immunity within the skin and the relationship of the skin’s immune system to the development of skin cancers. He also has a special research interest in the regulation of the immune system by stress and the nervous system. He was the first to demonstrate that certain immune cells within the skin are capable of initiating an immune response against a malignant tumor and that immune cells within the epidermis (the upper layer of the skin) have an anatomic relationship with nerves and can be regulated by proteins produced by those nerves. His clinical interests include autoimmune disorders of the skin, skin cancer, and psoriasis. [/three_fourths_last] [one_fourth]Dr. Robert K. Prud’homme [/one_fourth] [three_fourths_last] Dr. Prud’homme is a Professor of Chemical and Biological Engineering and Director of the Program in Engineering Biology at Princeton University. He received his Bachelor’s of Science at Stanford University in 1969 completed Special Studies in Environmental Science and Public Policy at Harvard University in 1973 and received his Ph.D. at The University of Wisconsin in 1978. Dr. Prud’homme’s work focuses on how weak forces at the molecular level determine macroscopic properties at larger length scales. He spends equal time understanding the details of molecular-level interactions using NMR, neutron scattering, x-ray scattering, or electron microscopy and making measurements of bulk properties such as rheology, diffusion of proteins in gels, drop sizes of sprays, or pressure drop measurements in porous media. Areas of concentration also include concentrated surfactant phases, polymer-surfactant phases, vesicles and liposomes, polymer assembly for control of wax, polymer-drug nano particle formation, biopolymers and emulsions. His work is highly interdisciplinary; many of the projects involve joint advisors and collaborations with researchers at NIH, Argonne National Labs, CNRS in France, and major corporate research teams. [/three_fourths_last][one_fourth]Daniel C. Baker, MD, FACS [/one_fourth] [three_fourths_last] Dr. Daniel Baker is one of the most exclusive and renowned plastic surgeons in the world. He is a Professor of Surgery at New York University Medical School and The Institute for Reconstructive Plastic Surgery. He has been teaching plastic surgeons for over 30 years, and has been invited to lecture and perform surgical demonstrations for plastic surgeons in over 30 countries around the world. Every year he lectures and teaches at numerous National Meetings in the United States and International Meetings around the world. He is a recognized figure in the field of surgical facial rejuvenation, and was the first to popularize the short-scar facelift procedure. He received his medical degree from Columbia University College of Physicians and Surgeons, his plastic surgery training at NYU Medical Center and then completed a fellowship in Head and Neck Cancer and Reconstructive Surgery at Columbia University. [/three_fourths_last]
[one_fourth]Sherrell J. Aston, MD, FACS [/one_fourth] [three_fourths_last]Dr. Sherrell J. Aston is a board-certified plastic surgeon and is considered one of the foremost international experts in aesthetic plastic surgery. He is a past President of the American Society for Aesthetic Plastic Surgery. He is currently the Surgeon Director and Chairman of the Department of Plastic Surgery at the Manhattan Eye, Ear and Throat Hospital in New York. He also serves as a Professor of Plastic Surgery at the New York University School of Medicine and Institute of Reconstructive Plastic Surgery. Dr. Aston received his Medical Degree from the University of Virginia, in Charlottesville, Virginia. His post-doctoral training included a surgical internship and residency at the University California, Los Angeles (UCLA) Medical Center. Prior to being Chief Resident at UCLA, he was a Halsted Fellow in Surgery at John Hopkins Hospital. Dr. Aston continued his training as a Plastic Surgery Resident and Chief Resident at the Institute of Reconstructive Plastic Surgery, New York University Medical Center. Dr. Aston has been recognized with numerous awards and honors.[/three_fourths_last]
[/full_width_section] [full_width_section bg_pos=”Left Top” bg_repeat=”No-Repeat” text_color=”Light” image_url=”” top_padding=”60″ bottom_padding=”35″ background_color=”#336699″]
Think we make a good match? [button color=”See-Through” size=”medium” url=”mailto:firstname.lastname@example.org” text=”Get In Touch”]
[/full_width_section] [full_width_section bg_pos=”Left Top” bg_repeat=”Repeat” text_color=”Dark” image_url=”http://themenectar.com/demo/salient/wp-content/uploads/2013/08/grid-bg1.jpg” top_padding=”90″ bottom_padding=”90″ background_color=””]